Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI: Current and future applications

Thomas A. Hope; Ali Afshar-Oromieh; Matthias Eiber; Louise Emmett; Wolfgang P. Fendler; Courtney Lawhn-Heath; Steven P. Rowe

doi:10.2214/AJR.18.19957

Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI: Current and future applications

Thomas A. Hope, Ali Afshar-Oromieh, Matthias Eiber, Louise Emmett, Wolfgang P. Fendler, Courtney Lawhn-Heath, Steven P. Rowe

School of Medicine

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

OBJECTIVE. The purpose of this article is to describe the large number of radiotracers being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prostate cancer. CONCLUSION. PSMA PET is a highly promising modality for the staging of prostate cancer because of its higher detection rate compared with that of conventional imaging. Both PET/CT and PET/MRI offer benefits with PSMA radiotracers, and PSMA PET findings frequently lead to changes in management. It is imperative that subsequent treatment changes be evaluated to show improved outcomes. PSMA PET also has potential applications, including patient selection for PSMA-based radioligand therapy and evaluation of treatment response.

Original language	English (US)
Pages (from-to)	286-294
Number of pages	9
Journal	American Journal of Roentgenology
Volume	211
Issue number	2
DOIs	https://doi.org/10.2214/AJR.18.19957
State	Published - Aug 2018

Keywords

PET
PET/MRI
Prostate cancer
Prostate-specific membrane antigen

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.2214/AJR.18.19957

Cite this

@article{c96b1d6f09e9440d9d62984926b8317c,

title = "Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI: Current and future applications",

abstract = "OBJECTIVE. The purpose of this article is to describe the large number of radiotracers being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prostate cancer. CONCLUSION. PSMA PET is a highly promising modality for the staging of prostate cancer because of its higher detection rate compared with that of conventional imaging. Both PET/CT and PET/MRI offer benefits with PSMA radiotracers, and PSMA PET findings frequently lead to changes in management. It is imperative that subsequent treatment changes be evaluated to show improved outcomes. PSMA PET also has potential applications, including patient selection for PSMA-based radioligand therapy and evaluation of treatment response.",

keywords = "PET, PET/MRI, Prostate cancer, Prostate-specific membrane antigen",

author = "Hope, {Thomas A.} and Ali Afshar-Oromieh and Matthias Eiber and Louise Emmett and Fendler, {Wolfgang P.} and Courtney Lawhn-Heath and Rowe, {Steven P.}",

note = "Funding Information: T. A. Hope received funding from the Prostate Cancer Foundation Young Investigator Award. Publisher Copyright: {\textcopyright} American Roentgen Ray Society.",

year = "2018",

month = aug,

doi = "10.2214/AJR.18.19957",

language = "English (US)",

volume = "211",

pages = "286--294",

journal = "American Journal of Roentgenology",

issn = "0361-803X",

publisher = "American Roentgen Ray Society",

number = "2",

}

TY - JOUR

T1 - Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI

T2 - Current and future applications

AU - Hope, Thomas A.

AU - Afshar-Oromieh, Ali

AU - Eiber, Matthias

AU - Emmett, Louise

AU - Fendler, Wolfgang P.

AU - Lawhn-Heath, Courtney

AU - Rowe, Steven P.

N1 - Funding Information: T. A. Hope received funding from the Prostate Cancer Foundation Young Investigator Award. Publisher Copyright: © American Roentgen Ray Society.

PY - 2018/8

Y1 - 2018/8

N2 - OBJECTIVE. The purpose of this article is to describe the large number of radiotracers being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prostate cancer. CONCLUSION. PSMA PET is a highly promising modality for the staging of prostate cancer because of its higher detection rate compared with that of conventional imaging. Both PET/CT and PET/MRI offer benefits with PSMA radiotracers, and PSMA PET findings frequently lead to changes in management. It is imperative that subsequent treatment changes be evaluated to show improved outcomes. PSMA PET also has potential applications, including patient selection for PSMA-based radioligand therapy and evaluation of treatment response.

AB - OBJECTIVE. The purpose of this article is to describe the large number of radiotracers being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prostate cancer. CONCLUSION. PSMA PET is a highly promising modality for the staging of prostate cancer because of its higher detection rate compared with that of conventional imaging. Both PET/CT and PET/MRI offer benefits with PSMA radiotracers, and PSMA PET findings frequently lead to changes in management. It is imperative that subsequent treatment changes be evaluated to show improved outcomes. PSMA PET also has potential applications, including patient selection for PSMA-based radioligand therapy and evaluation of treatment response.

KW - PET

KW - PET/MRI

KW - Prostate cancer

KW - Prostate-specific membrane antigen

UR - http://www.scopus.com/inward/record.url?scp=85052388103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052388103&partnerID=8YFLogxK

U2 - 10.2214/AJR.18.19957

DO - 10.2214/AJR.18.19957

M3 - Article

C2 - 29949419

AN - SCOPUS:85052388103

SN - 0361-803X

VL - 211

SP - 286

EP - 294

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

IS - 2

ER -

Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI: Current and future applications

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this